FDA Approves Lantheus' BRAVNETSA as First Bioequivalent to LUTATHERA for GEP-NETs
LNTH has more than doubled off its 52-week low of $49.67.
Summary
The FDA granted final approval to BRAVNETSA, Lantheus' lutetium Lu 177 dotatate, as the only radiopharmaceutical determined bioequivalent and therapeutically equivalent to Novartis' LUTATHERA for GEP-NETs. This is a significant regulatory milestone that opens a new ANDA pathway for radioligand therapies and positions Lantheus to compete directly in the established LUTATHERA market. The approval comes amid Lantheus' pending $8B acquisition by Curium, with a shareholder vote scheduled for October 14. Commercial launch timing and supply readiness will be key near-term factors, but the approval itself validates the product and expands the company's oncology portfolio.
At the time of this announcement, LNTH was trading at $99.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $49.67 to $111.86. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.